Top Section/Ad
Top Section/Ad
Most recent
Shareholders sell down holdings in AutoStore and Orsted, as shipping company opens books ahead of Athens parallel listing
Deeply discounted financing allows embattled iron ore miner to restart Ukrainian production and shares to resume trading
International investors take most of the book for the first time as Zabłocki's investment firm says it expects to make no further sales
Food systems company’s largest shareholder raises €324m after shares rise on strong results and buyback
More articles/Ad
More articles/Ad
More articles
-
Russian equity capital markets are red hot again, after almost two years in the cold, with supply being driven by some of Russia’s most powerful oligarchs. As investors warm to Russian equities, more of these billionaires are set to monetise some of their holdings, writes Sam Kerr. -
ECM investors continue to support Russian deals and flooded into a Rub5.8bn ($89m) block in LSR Group, the Russian real estate development company, in what was the latest sell-down by one of the country’s oligarchs.
-
Kaupthing Bank has completed the first selldown of shares in Arion Banki, the Icelandic bank that was rescued during the financial crisis, since its re-IPO last year.
-
A recent resurgence in Russian ECM has gathered pace with the announcement of two IPOs in London and the US, as oligarchs seize the opportunity of a better equity window. Rustranscom (RTC), the Russian freight transportation company, joined this wave after it filed paperwork for a London listing of global depository receipts on Monday evening.
-
AstraZeneca, the British-Swedish pharmaceuticals giant, has priced a historic £2.7bn accelerated transaction ($3.5bn) to fund a transformational oncology collaboration. But sources close to the deal say that execution was complicated by Brexit drama last Friday.
-
Pharmaceutical giant AstraZeneca has entered into a collaboration agreement with Japanese pharmaceutical company Daiichi Sankyo to develop a new antibody-drug conjugate which it is hoped will revolutionise cancer treatment. The deal is being funded through an equity capital raise.
